DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award
This cooperative agreement funds development of a breast cancer consortium framework and preliminary research with active consumer advocate participation, to support a future BCRP Transformative Breast Cancer Consortium application.
⚑ Applicants must address at least one FY26 BCRP overarching challenge or justify an exception. · Breast cancer consumer advocates must be active participants in both development and execution. · Consortium Director may be named on only one of the two FY26 consortium award mechanisms (development award or full consortium award). · No award ceiling listed in notice ($0 shown).
Unit fits — one characterization, each unit's own rules
| IPPRA | 84 strong | portfolio topic: public_health; social/behavioral work is substantial; funds basic research |
| Physical Sciences & Engineering (demo) | 55 good | technical depth: minor; funds basic research |
| Tom Love Innovation Hub | 15 none | deep-tech content; no commercialization signal |
Description
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Development Award provides successful applicants the time and resources needed to bring investigators and breast cancer consumer advocates together to establish a consortium framework and conduct preliminary research in support of an application to a future, full BCRP Transformative Breast Cancer Consortium Award (pending availability of funds). All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.
Distinctive Features:
· This is a development award and is a separate award mechanism from the full FY26 BCRP Transformative Breast Cancer Consortium Award (HT942526BCRPTBCCA). For FY26, investigators may be named as Consortium Director on an application submitted to either (but not both) of these award mechanisms.
· Breast cancer consumer advocates must be active participants in the development and execution of the FY26 BCRP TBCCDA.
Apply
View on Grants.gov → CONTACT: Jamie Shortall Grant Officer <help@eBRAP.org>
Proposal brief
Proposal shell · Department of Defense (BAA-style) conventions
Legacy IPPRA LLM assessment (v2.0, for comparison)
18/100 · gpt-5.4-mini · 2026-07-06
This is a breast cancer program focused on consortium development and preliminary research, so the topic is within public health but not within IPPRA’s core strengths in health communication, behavioral intervention, or population data research. The required consumer advocate participation adds a community-engagement element, but the opportunity is not primarily a research or survey program at the policy/behavioral intersection IPPRA typically leads. Eligibility appears oriented to the BCRP and does not clearly exclude public universities, but the fit remains weak.
Legacy scoring history
| 2026-07-06 | 18 | gpt-5.4-mini | This is a breast cancer program focused on consortium development and preliminary research, so the topic is within public health but not within IPPRA’s core strengths in health communication, behavioral intervention, or population data research. The required consumer advocate participation adds a community-engagement element, but the opportunity is not primarily a research or survey program at the policy/behavioral intersection IPPRA typically leads. Eligibility appears oriented to the BCRP and does not clearly exclude public universities, but the fit remains weak. |
| 2026-07-06 | 0 | gpt-5.4-mini | This opportunity is focused on breast cancer consortium development and requires a direct breast-cancer research agenda, which is outside IPPRA’s core portfolio areas. The notice also appears to be a DoD/Defense Health Award for breast cancer; even if public universities may be eligible, the topic has no meaningful weather, energy, national security, or policy-research overlap for IPPRA. |